- Home
- FENC vs CERS Comparison
FENC vs CERS Comparison
Compare FENC & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | CERS |
|---|---|---|
| Founded | 1996 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.5M | 276.0M |
| IPO Year | 2001 | 1997 |
Fundamental Metrics
Financial Performance| Metric | FENC | CERS |
|---|---|---|
| Price | $7.58 | $2.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $13.50 | $4.00 |
| AVG Volume (30 Days) | 154.3K | ★ 1.8M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $38,790,000.00 | ★ $199,191,000.00 |
| Revenue This Year | N/A | $25.31 |
| Revenue Next Year | $75.22 | $9.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.03 |
| 52 Week Low | $4.68 | $1.12 |
| 52 Week High | $9.92 | $2.26 |
Technical Indicators
Market Signals| Indicator | FENC | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 59.26 |
| Support Level | $7.50 | $2.01 |
| Resistance Level | $8.00 | $2.26 |
| Average True Range (ATR) | 0.29 | 0.15 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 43.08 | 62.77 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.